-
公开(公告)号：US20080213260A1
公开(公告)日：2008-09-04
申请号：US11840576
申请日：2007-08-17
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/39541 , A61K39/39558 , A61K47/6829 , A61K47/6849 , A61K2039/505 , A61K2039/507 , C07K16/283 , C07K16/2851 , C07K16/2887 , C07K16/2896 , C07K2317/24 , C07K2317/73 , C07K2317/732 , C07K2317/75 , A61K2300/00
摘要： Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
-
公开(公告)号：US20080213168A1
公开(公告)日：2008-09-04
申请号：US11840580
申请日：2007-08-17
IPC分类号： A61K51/10 , A61K39/395 , A61P35/04
CPC分类号： A61K39/39541 , A61K39/39558 , A61K47/6829 , A61K47/6849 , A61K2039/505 , A61K2039/507 , C07K16/283 , C07K16/2851 , C07K16/2887 , C07K16/2896 , C07K2317/24 , C07K2317/73 , C07K2317/732 , C07K2317/75 , A61K2300/00
摘要： Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
摘要翻译： 提供了用于治疗包括使用CD23拮抗剂的肿瘤性疾病的方法和试剂盒。 CD23拮抗剂可以单独使用或与化学治疗剂组合使用。 在特别优选的实施方案中，CD23拮抗剂可用于治疗B细胞慢性淋巴细胞白血病（B-CLL）。
-
公开(公告)号：US20080171056A1
公开(公告)日：2008-07-17
申请号：US11840584
申请日：2007-08-17
IPC分类号： A61K39/395 , C12N5/08 , A61P35/02
CPC分类号： A61K39/39541 , A61K39/39558 , A61K47/6829 , A61K47/6849 , A61K2039/505 , A61K2039/507 , C07K16/283 , C07K16/2851 , C07K16/2887 , C07K16/2896 , C07K2317/24 , C07K2317/73 , C07K2317/732 , C07K2317/75 , A61K2300/00
摘要： Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
-
公开(公告)号：US20080213167A1
公开(公告)日：2008-09-04
申请号：US11840573
申请日：2007-08-17
IPC分类号： A61K51/10 , A61K39/395 , A61P35/04
CPC分类号： A61K39/39541 , A61K39/39558 , A61K47/6829 , A61K47/6849 , A61K2039/505 , A61K2039/507 , C07K16/283 , C07K16/2851 , C07K16/2887 , C07K16/2896 , C07K2317/24 , C07K2317/73 , C07K2317/732 , C07K2317/75 , A61K2300/00
摘要： Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
-
公开(公告)号：US20060286101A1
公开(公告)日：2006-12-21
申请号：US11464135
申请日：2006-08-11
IPC分类号： A61K39/395
CPC分类号： A61K39/39541 , A61K39/39558 , A61K47/6829 , A61K47/6849 , A61K2039/505 , A61K2039/507 , C07K16/283 , C07K16/2851 , C07K16/2887 , C07K16/2896 , C07K2317/24 , C07K2317/73 , C07K2317/732 , C07K2317/75 , A61K2300/00
摘要： Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
摘要翻译： 提供了用于治疗包括使用CD23拮抗剂的肿瘤性疾病的方法和试剂盒。 CD23拮抗剂可以单独使用或与化学治疗剂组合使用。 在特别优选的实施方案中，CD23拮抗剂可用于治疗B细胞慢性淋巴细胞白血病（B-CLL）。
-
公开(公告)号：US20060171950A1
公开(公告)日：2006-08-03
申请号：US11277982
申请日：2006-03-30
IPC分类号： A61K39/395 , C07K16/44 , C07K16/30
CPC分类号： A61K39/39541 , A61K39/39558 , A61K47/6829 , A61K47/6849 , A61K2039/505 , A61K2039/507 , C07K16/283 , C07K16/2851 , C07K16/2887 , C07K16/2896 , C07K2317/24 , C07K2317/73 , C07K2317/732 , C07K2317/75 , A61K2300/00
摘要： Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
摘要翻译： 提供了用于治疗包括使用CD23拮抗剂的肿瘤性疾病的方法和试剂盒。 CD23拮抗剂可以单独使用或与化学治疗剂组合使用。 在特别优选的实施方案中，CD23拮抗剂可用于治疗B细胞慢性淋巴细胞白血病（B-CLL）。
-
公开(公告)号：US07319139B2
公开(公告)日：2008-01-15
申请号：US10058069
申请日：2002-01-29
IPC分类号： C12P21/08 , C07K16/00 , A61K39/395 , C12P21/04 , C12N5/06
CPC分类号： C12P21/02 , A61K47/6849 , A61K47/6851 , A61K47/6869 , A61K47/6901 , A61K51/1027 , A61K51/1045 , A61K51/1072 , A61K2039/505 , C07K16/00 , C07K16/2896 , C07K16/30 , C07K16/3069 , C07K2317/24 , C07K2317/52 , C07K2319/00 , C12N15/85
摘要： Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same antigen binding specificity (homodimers) or, alternatively, may comprise two different antibody molecules having binding specificity for two distinct antigens (heterodimers). In preferred embodiments the antibody molecules comprising the dimers are non-covalently associated.
摘要翻译： 提供了包含用于治疗肿瘤，自身免疫或其它病症的二聚抗体的方法，组合物和试剂盒。 本发明的二聚体抗体可以包含具有相同抗原结合特异性（同源二聚体）的两个抗体分子（H 4 S 4 L 4），或者可以包含两种不同的抗体 对两种不同抗原（异二聚体）具有结合特异性的分子。 在优选的实施方案中，包含二聚体的抗体分子是非共价缔合的。
-
公开(公告)号：US06897044B1
公开(公告)日：2005-05-24
申请号：US09238741
申请日：1999-01-28
IPC分类号： C12N15/09 , A61K39/395 , A61K47/48 , A61P1/00 , A61P11/00 , A61P11/02 , A61P11/06 , A61P17/00 , A61P35/00 , A61P37/02 , A61P37/08 , C07K16/28 , C07K16/46 , C12P21/08 , C12N15/00
CPC分类号： C07K16/2887 , A61K47/6835 , A61K2039/505 , C07K16/2851 , C07K16/468 , C07K2317/31 , C07K2317/734
摘要： The present invention relates to a novel process for the preparation of biologically active antibody dimers in a pharmaceutically acceptable composition. The dimers can be composed of two antibody molecules having the same antigen binding specificity and linked through reducible, disulfide, or a non-reducible thioether, bond (homodimer). Alternatively, the dimers can be composed of two different antibody molecules having binding specificity for two distinct antigens (heterodimer). These dimers are useful for inducing hyper-cross-linking of membrane antigens. The present invention further relates to the use of biologically active antibody dimers for the preferential killing or inhibition of selected cell populations in the treatment of diseases such as cancer and autoimmune disorders.
摘要翻译： 本发明涉及一种用于在药学上可接受的组合物中制备生物活性抗体二聚体的新方法。 二聚体可以由具有相同抗原结合特异性的两个抗体分子组成并通过可还原的二硫键或不可还原的硫醚键（同二聚体）连接。 或者，二聚体可以由对两种不同抗原（异二聚体）具有结合特异性的两种不同抗体分子组成。 这些二聚体可用于诱导膜抗原的超交联。 本发明还涉及生物活性抗体二聚体在优先杀死或抑制所选细胞群体治疗诸如癌症和自身免疫疾病的疾病中的用途。
-
公开(公告)号：US06998125B2
公开(公告)日：2006-02-14
申请号：US09853581
申请日：2001-05-14
IPC分类号： A61K39/385 , A61K39/395
CPC分类号： A61K39/00 , A61K9/1075 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K39/39558 , A61K2039/505 , A61K2039/55516 , A61K2039/55522 , A61K2039/55555 , A61K2039/55566 , A61K2039/57 , A61K2039/585 , C07K16/22 , C07K2317/76 , C12N2710/20034 , Y02A50/412 , Y02A50/464 , A61K2300/00
摘要： The present invention provides a synergistic composition and methods for treating neoplastic or cancerous growths as well as for treating such patients in order to restore or boost hematopoiesis. The present invention comprises administration of the combination of a cytotoxic T-lymphocyte inducing composition and at least one agent which is capable of neutralizing or down regulating the activity of tumor secreted immunosuppressive factors, separately or in combination.
-
公开(公告)号：US20070280881A1
公开(公告)日：2007-12-06
申请号：US10058069
申请日：2002-01-29
申请人： Gary Braslawsky , Nabil Hanna , Paul Chinn , Kandasamy Hariharan
发明人： Gary Braslawsky , Nabil Hanna , Paul Chinn , Kandasamy Hariharan
IPC分类号： A61K51/00 , A61K39/395 , C07K16/30 , C07K16/46
CPC分类号： C12P21/02 , A61K47/6849 , A61K47/6851 , A61K47/6869 , A61K47/6901 , A61K51/1027 , A61K51/1045 , A61K51/1072 , A61K2039/505 , C07K16/00 , C07K16/2896 , C07K16/30 , C07K16/3069 , C07K2317/24 , C07K2317/52 , C07K2319/00 , C12N15/85
摘要： Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same antigen binding specificity (homodimers) or, alternatively, may comprise two different antibody molecules having binding specificity for two distinct antigens (heterodimers). In preferred embodiments the antibody molecules comprising the dimers are non-covalently associated.
摘要翻译： 提供了包含用于治疗肿瘤，自身免疫或其它病症的二聚抗体的方法，组合物和试剂盒。 本发明的二聚体抗体可以包含具有相同抗原结合特异性（同源二聚体）的两个抗体分子（H 4 S 4 L 4），或者可以包含两种不同的抗体 对两种不同抗原（异二聚体）具有结合特异性的分子。 在优选的实施方案中，包含二聚体的抗体分子是非共价缔合的。
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.029 秒)
